Raven-incubated portfolio company Aliada Therapeutics was acquired by AbbVie for $1.4 billion in December 2024.
Aliada Therapeutics is a neuroscience-focused company working towards overcoming the delivery hurdle in large molecule drug development
Aliada Therapeutics is a neuroscience-focused company working towards overcoming the delivery hurdle in large molecule drug development. Aliada is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness.